Oppenheimer Sticks to Their Buy Rating for SAB Biotherapeutics (SABS)
Oppenheimer analyst Leland Gershell maintained a Buy rating on SAB Biotherapeutics (SABS – Research Report) today and set a price target ...
Techmediabreaks Calidi Biotherapeutics Inc. (NYSE American: CLDI) Announces Public Offering To Support Immunotherapy Development
Calidi Biotherapeutics (NYSE American: CLDI) has announced plans to sell shares of its common stock and/or pre-funded warrants in a <a target ...
BTIG Sticks to Its Buy Rating for Spyre Therapeutics (SYRE)
In a report released today, Julian Harrison from BTIG maintained a Buy rating on Spyre Therapeutics (SYRE – Research Report), with a ...
Alan Fournier's Strategic Moves in Q3 2024: A Deep Dive into TransDigm Group's Significant Reduction
Alan Fournier ( Trades, Portfolio )'s portfolio welcomed a new entrant in the third quarter of 2024: The most significant ...
Hosted on MSN7d
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call Transcript
Arcutis Biotherapeutics, Inc. (NASDAQ ... we are building a broad portfolio of ZORYVE solutions for clinicians in a multitude ...
Yahoo Finance29d
Calidi Biotherapeutics and Gorilla Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / October 18, 2024 / RedChip Companies will air interviews with Calidi Biotherapeutics ... leader in delivering transformative solutions that drive large-scale digital ...
75+ Key Companies Charting New Frontiers in Multiple Sclerosis Therapeutic Space | DelveInsight
DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...
Morningstar24d
Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies
Innovative approaches, like in vivo CAR gene therapies, have the potential to transform how we treat cancer, offering faster, single-dose solutions ... Interius BioTherapeutics is a clinical ...
Future Market Insights17h
Animal Model Market to Reach USD 3,476.8 Million by 2034, Growing at a 6% CAGR
The global animal model market is expected to grow from USD 1,943.3 million in 2024 to USD 3,476.8 million by 2034, at a CAGR ...
Pharmabiz22d
Thermo Fisher Scientific & Telangana government partner to set-up bioprocess design centre to advance novel biotherapeutics in India
the bioprocess design centre will become operational in early 2025 and serve as a benchmark to accelerate the development and manufacturing of innovative biotherapeutics in ... and cutting-edge ...